Moderna, Inc. (MRNA)
Biological Products, (No Diagnostic Substances)
Latest Price
$54.82
TTM P/E
--
Normalized P/E
38.07
Div Yield
--
Book Value
18.75
P/B Ratio
2.92
Valuation metrics
adjust assumptions →Base FCF: $9.0B (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$392.82
+617% upside
Institutional Ownership
85.8% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 45.67M | $2.32B | 11.50% | +17.63M | 2026-03-31 |
| BlackRock, Inc. | 29.64M | $1.50B | 7.46% | -2.87M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 22.87M | $1.16B | 5.76% | -- | 2026-03-31 |
| BAILLIE GIFFORD & CO | 19.99M | $1.01B | 5.03% | -594.6K | 2026-03-31 |
| Capital World Investors | 18.70M | $949.0M | 4.71% | +5.87M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.62M | $793.0M | 3.93% | -- | 2026-03-31 |
| STATE STREET CORP | 14.86M | $754.0M | 3.74% | -1.50M | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 9.44M | $478.0M | 2.38% | +215.5K | 2026-03-31 |
| MORGAN STANLEY | 8.47M | $430.0M | 2.13% | -399.5K | 2026-03-31 |
| UBS Group AG | 8.34M | $423.0M | 2.10% | -6.43M | 2026-03-31 |